Effect and Safety of Pertuzumab in the Treatment of Patients with HER2-positive Breast Cancer
Objective:To explore the efficacy and safety of Pertuzumab in HER2-positive breast cancer and its influence on T lymphocyte subsets and NK cell.Method:A total of 100 patients with HER2-positive breast cancer admitted to Yancheng Second People's Hospital from January 2021 to January 2023 were divided into control group and observation group according to random number table method,with 50 cases in each group.The control group was treated with Trastuzumab combined with Docetaxel,and the observation group was treated with Pertuzumab on the basis of the control group.The total effective rate,the incidence of toxic and side effects,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 15-3(CA15-3)and carbohydrate antigen 125(CA125)],quality of life[functional assessment of cancer therapy-breast(FACT-B)],T lymphocyte subsets(CD3+and CD4+),NK cell before and after treatment were compared bewteen the tow groups.Result:The total effective rate of observation group was significantly higher than that of control group(P<0.05).There were no significant differences in the incidence of toxic and side effects between the two groups(P>0.05).Before treatment,there were no significant differences in tumor markers,FACT-B scores,T lymphocyte subsets and NK cell between the two groups(P>0.05);after two courses of treatment,tumor markers in observation group were significantly lower than those in control group,FACT-B scores,T lymphocyte subsets and NK cell were significantly higher than those in control group(P<0.05).Conclusion:The effect of Pertuzumab in HER2-positive breast cancer is better,the safety is worthy of recognition,and its influence on T lymphocyte subsets and NK cell is less.
PertuzumabHER2-positive breast cancerSafetyT lymphocyte subsetsNK cell
万方数据
维普
